Vivani Medical VANI Biopharm Division — Total Assets
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vivani Medical in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The official record: Vivani Medical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vivani Medical's biopharm division — total assets.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vivani Medical's biopharm division — total assets?
- Vivani Medical (VANI) reported biopharm division — total assets of $41.9M in Q1 2026.
- How has Vivani Medical's biopharm division — total assets changed year-over-year?
- Vivani Medical's biopharm division — total assets increased by 20.7% year-over-year, from $34.7M to $41.9M.
- What does biopharm division — total assets mean?
- Reflects the total economic resources controlled by the biopharmaceutical segment, including intellectual property, laboratory equipment, and capitalized development costs. This metric provides insight into the asset base supporting the segment's research capabilities and long-term value creation potential. It is a key indicator of the segment's capacity to execute its proprietary technology development strategy.